XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.1

License Agreements (Details) - Nucynta Products - USD ($) $ in Thousands		1 Months Ended
	Feb. 13, 2020	Nov. 30, 2018
Grnenthal
License Agreements [Line Items]
Royalty payment as percentage of annual net sales	14.00%
Third Amendment to the Nucynta Commercialization Agreement | Maximum | Sales Royalty Structure 1
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021		$ 210,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 1
License Agreements [Line Items]
Royalty payment as percentage of annual net sales		65.00%
Royalty payment limit between January 1, 2019 and December 31, 2021		$ 180,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 2
License Agreements [Line Items]
Royalty payment as percentage of annual net sales		14.00%
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 3
License Agreements [Line Items]
Royalty payment as percentage of annual net sales		58.00%
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 4
License Agreements [Line Items]
Royalty payment as percentage of annual net sales		20.00%
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 5
License Agreements [Line Items]
Royalty payment as percentage of annual net sales		15.00%
Royalty payment limit between January 1, 2019 and December 31, 2021		$ 258,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Minimum | Sales Royalty Structure 2
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021		180
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Minimum | Sales Royalty Structure 3
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021		210,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Minimum | Sales Royalty Structure 5
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021		233,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Maximum | Sales Royalty Structure 3
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021		233,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Maximum | Sales Royalty Structure 5
License Agreements [Line Items]
Royalty payment limit between January 1, 2019 and December 31, 2021		$ 258,000
Nucynta Purchase Agreement | Grnenthal
License Agreements [Line Items]
Royalty payment as percentage of annual net sales	14.00%

X

- Definition

Represents the royalty payment as percentage of annual net sales.

+ References

No definition available.

+ Details

Name:	coll_CollaborativeArrangementRoyaltyPaymentAsPercentageOfAnnualNetSales
Namespace Prefix:	coll_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Arrangement, Royalty Payment Limit

+ References

No definition available.

+ Details

Name:	coll_CollaborativeArrangementRoyaltyPaymentLimit
Namespace Prefix:	coll_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

License Agreements [Line Items]

+ References

No definition available.

+ Details

Name:	coll_LicenseAgreementsLineItems
Namespace Prefix:	coll_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=coll_NucyntaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=coll_GrnenthalGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=coll_ThirdAmendmentToCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=coll_SalesRoyaltyStructure1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=coll_AssertioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=coll_SalesRoyaltyStructure2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=coll_SalesRoyaltyStructure3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=coll_SalesRoyaltyStructure4Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=coll_SalesRoyaltyStructure5Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=coll_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: